Strategic considerations

Acute myeloid leukemia (AML), also referred to as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a relatively rare, yet aggressive, type of cancer. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with AML receiving venetoclax.

Data from up to 700 participants will be collected. No participants will be enrolled in this study.

Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 10 months.

There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 10 months.

Inclusion Criteria:

• The participant received a diagnosis for acute myeloid leukemia (AML).
• The participant was initiated on the studied line of therapy for previously untreated AML, as noted in the protocol.
• The participant was treated with the studied line of therapy at least 28 days prior to date of data collection.
• Information on the participant's treatments, selected (or important) clinical characteristics, and outcomes is available from the start of the studied line of therapy onwards.

Exclusion Criteria:

• The participant received the studied line of therapy as part of a clinical trial.
• Participant received prior lines of therapy for AML.
• The participant has a history of malignancies within 2 years prior to the studied line of therapy, other than AML, and with the exception of what is noted in the protocol.

Adult Participants with Acute Myeloid Leukemia (AML) being treated with venetoclax.